| 21.1897 0.22 (1.05%) | 12-08 12:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.08  |
1-year : | 29.29 |
| Resists | First : | 21.47 |
Second : | 25.08 |
| Pivot price | 20.6 |
|||
| Supports | First : | 20.12 |
Second : | 19.29 |
| MAs | MA(5) : | 20.83 |
MA(20) : | 20.66 |
| MA(100) : | 15.69 |
MA(250) : | 0 | |
| MACD | MACD : | 0.5 |
Signal : | 0.6  |
| %K %D | K(14,3) : | 81.8 |
D(3) : | 68.4 |
| RSI | RSI(14): 64.8 |
|||
| 52-week | High : | 21.47 | Low : | 8.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ROIV ] has closed below upper band by 7.0%. Bollinger Bands are 31.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.35 - 21.48 | 21.48 - 21.59 |
| Low: | 20.55 - 20.69 | 20.69 - 20.81 |
| Close: | 20.78 - 20.99 | 20.99 - 21.18 |
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Mon, 08 Dec 2025
Roivant Sciences stock hits all-time high at $21.36 By Investing.com - Investing.com Canada
Mon, 08 Dec 2025
Roivant Sciences Ltd. $ROIV is SB Investment Advisers UK Ltd.'s 3rd Largest Position - MarketBeat
Sun, 07 Dec 2025
88,495 Shares in Roivant Sciences Ltd. $ROIV Acquired by Franklin Resources Inc. - MarketBeat
Fri, 05 Dec 2025
Roivant Sciences Ltd. $ROIV Position Increased by Two Seas Capital LP - MarketBeat
Fri, 05 Dec 2025
Roivant Sciences Ltd. $ROIV Shares Sold by Pertento Partners LLP - MarketBeat
Thu, 13 Nov 2025
Roivant Sciences: Brepocitinib And Roadmap Still Underpriced (NASDAQ:ROIV) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 695 (M) |
| Held by Insiders | 4.8595e+008 (%) |
| Held by Institutions | 25.3 (%) |
| Shares Short | 25,270 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.11e+009 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -18 % |
| Return on Assets (ttm) | 595.3 % |
| Return on Equity (ttm) | -12.5 % |
| Qtrly Rev. Growth | 2.033e+007 % |
| Gross Profit (p.s.) | -52.77 |
| Sales Per Share | -14.12 |
| EBITDA (p.s.) | -4.72943e+008 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -770 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.51 |
| Price to Cash Flow | 4.12 |
| Dividend | 0 |
| Forward Dividend | 2.305e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|